Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years

Kris V. Kowdley; Christopher L. Bowlus; C Levy; Ulus Salih Akarca; Mário Reis Álvares‐da‐Silva; Pietro Andreoné; Marco Arrese; Christophe Corpechot; Hany Elbeshbeshy; Sven Francque; Michael A. Heneghan; Pietro Luigi Invernizzi; Ira M. Jacobson; D. I. Jones; Frederik C. Kruger; Eric Lawitz; Marlyn J. Mayo; Mitchell L. Shiffman; Mark Sonderup; Mark G. Swain; José Miguel Valera; Vı́ctor Vargas; J Vierling; Alejandra Villamil; Claire Raskino; Nuno Antunes; M-J Sleiman; Valeria Cranham; Benjamin K. Miller; Jörn M. Schattenberg

doi:10.1055/s-0045-1810778

Key Points

Elafibranor significantly improved cholestasis biomarkers after three years of treatment.
Biomarker enhancements were noted at Week 52 of the trial, with potential sustained effects.
The ELATIVE trial involved an open-label extension assessing long-term efficacy and safety.
These findings support ongoing investigation into elafibranor for managing primary biliary cholangitis.

Implication

Interim results demonstrate improved biomarkers in patients with primary biliary cholangitis, suggesting elafibranor's long-term benefits.

Abstract

Background: Elafibranor (ELA) significantly improved biomarkers of cholestasis at Week (W)52 in patients (pts) with primary biliary cholangitis (PBC) in the phase III ELATIVE trial (NCT04526665).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kowdley et al. (2025) studied this question.

synapsesocial.com/papers/68c193fb9b7b07f3a06184be https://doi.org/10.1055/s-0045-1810778

View at Publisher

Ask AI

Bookmark

Share

Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading